4 Stocks That Declared Dividend Hikes Amid Ongoing Economic Uncertainty
CNP, VAC, PCG and ZTS raised dividends as tech volatility and economic uncertainty push income-focused investors toward steadier stocks.
5 Stocks Worth Watching on Their Recent Dividend Hikes
PNR, NVT, CNP, VAC and PCG stand out as dividend payers as market volatility persists, with each company recently announcing higher shareholder payouts.
Here's My Prediction For Who Could Acquire Ascendis Pharma
Ascendis Pharma is rated a cautious buy amid acquisition speculation, robust revenue growth, and a pivotal FDA decision on TransCon CNP. Yorvipath and Skytrofa drove Q3 revenues to €213.6 million, nearly quadrupling year-over-year, with operating profitability achieved for the quarter. TransCon CNP, targeting achondroplasia, faces a critical FDA PDUFA date on February 28th, with multi-billion-euro TAM potential if approved.
Down 5.3% in 4 Weeks, Here's Why CenterPoint (CNP) Looks Ripe for a Turnaround
CenterPoint (CNP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
CenterPoint Energy: A Particularly Well-Positioned Utility
CenterPoint Energy targets 11% rate base and 7%-9% EPS growth through 2030, underpinned by a $65 billion 10-year capital plan. Robust demand growth in Texas, especially from data centers and industrial activity, drives a projected 50% peak load increase over six years. Strategic Ohio unit sale at 26x earnings funds cap-ex and accelerates CNP's Texas pure-play transition, reducing near-term equity issuance needs.
4 Low-Beta Defensive Stocks to Buy as Consumer Sentiment Plummets
ETR, CNP, JBSS and UVV stand out as consumer sentiment sinks, with low beta, rising earnings estimates and a steady dividend drawing defensive investors.
CenterPoint (CNP) Upgraded to Buy: Here's Why
CenterPoint (CNP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here's Why CNP Stock Deserves a Place in Your Portfolio Right Now
Rising power demand, steady payouts and aggressive capital strategy highlight CNP???s accelerating growth trajectory.
Is CenterPoint Energy (CNP) Outperforming Other Utilities Stocks This Year?
Here is how CenterPoint Energy (CNP) and IdaCorp (IDA) have performed compared to their sector so far this year.
CenterPoint (CNP) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for CenterPoint (CNP) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
CenterPoint Energy, Inc. (CNP) Q3 2025 Earnings Call Transcript
CenterPoint Energy, Inc. (NYSE:CNP ) Q3 2025 Earnings Call October 23, 2025 8:00 AM EDT Company Participants Ben Vallejo Jason Wells - President, CEO & Director Christopher Foster - Executive VP & CFO Conference Call Participants Nicholas Campanella - Barclays Bank PLC, Research Division Steven Fleishman - Wolfe Research, LLC Jeremy Tonet - JPMorgan Chase & Co, Research Division Julien Dumoulin-Smith - Jefferies LLC, Research Division Presentation Operator Good morning, and welcome to CenterPoint Energy's Third Quarter 2025 Earnings Conference Call with senior management. [Operator Instructions] I will now turn the call over to Ben Vallejo, Director of Investor Relations and Corporate Planning.
CenterPoint Energy (CNP) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does CenterPoint (CNP) have what it takes?
